These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34303849)

  • 41. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omicron: Call for updated vaccines.
    Li X
    J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
    Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
    Front Immunol; 2021; 12():692937. PubMed ID: 34497604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
    Volkan E
    Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.
    Kyei-Barffour I; Addo SA; Aninagyei E; Ghartey-Kwansah G; Acheampong DO
    Biomed Pharmacother; 2021 Dec; 144():112282. PubMed ID: 34624675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
    Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
    Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
    Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
    Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19 vaccinations: The unknowns, challenges, and hopes.
    Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics.
    Ebrahimi N; Aslani S; Babaie F; Hemmatzadeh M; Hosseinzadeh R; Joneidi Z; Mehdizadeh Tourzani Z; Pakravan N; Mohammadi H
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107082. PubMed ID: 33068865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020).
    Kim DS; Rowland-Jones S; Gea-Mallorquí E
    Front Immunol; 2020; 11():571481. PubMed ID: 33362759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T cell immunity to SARS-CoV-2 following natural infection and vaccination.
    DiPiazza AT; Graham BS; Ruckwardt TJ
    Biochem Biophys Res Commun; 2021 Jan; 538():211-217. PubMed ID: 33190827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Update on Innate Immune Responses during SARS-CoV-2 Infection.
    Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review).
    Shang J; Du L; Han N; Lv D; Wang J; Yang H; Bai L; Tang H
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.